Search Browse Earnings

KalVista Pharmaceuticals, Inc. — SlamSEC

KalVista Pharmaceuticals, Inc.

Nasdaq:KALV

Pharmaceutical Preparations·FRAMINGHAM, MA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$12.7M

-21.3% YoY

FY 2022

Adj. EBITDA

-$139.6M

-1100.3% margin

FY 2025

Net Income

-$126.6M

-998.0% margin

FY 2025

EPS (Diluted)

-$3.44

FY 2025

Stock Price

$17.30

+7.0%

2026-03-09

52W Range

$9.23 – $19.00

P/E Ratio

-5.0x

Market Cap

$874.5M

Cash

$31.8M

FY 2025

Total Debt

—

Net Cash

$31.8M

FY 2022

Enterprise Value

$842.7M

Debt / EBITDA

0.2x

FY 2022

EV / EBITDA

-6.0x

Employees

—